Pier Capital’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-144,850
Closed -$8.29M 134
2024
Q3
$8.29M Sell
144,850
-75,597
-34% -$4.33M 1.17% 34
2024
Q2
$11.5M Sell
220,447
-2,185
-1% -$95.8K 1.72% 2
2024
Q1
$9.06M Buy
222,632
+93,153
+72% +$3.49M 1.25% 32
2023
Q4
$4.79M Sell
129,479
-2,426
-2% -$91.4K 0.68% 70
2023
Q3
$5.04M Sell
131,905
-4,088
-3% -$167K 0.81% 66
2023
Q2
$4.91M Buy
135,993
+48,035
+55% +$1.64M 0.7% 74
2023
Q1
$3.36M Sell
87,958
-83,366
-49% -$3.91M 0.51% 93
2022
Q4
$9.75M Sell
171,324
-1,127
-0.7% -$57.7K 1.6% 7
2022
Q3
$6.82M Buy
+172,451
New +$7.62M 1.17% 39

Other funds holding HALO

Pier Capital's HALO Position: Q4 2024 in Review

Pier Capital sold out of Halozyme (HALO) in Q4 2024, closing a stake of 144,850 shares — an estimated $8.29M sold.

Pier Capital first reported a position in HALO in Q3 2022 and held it in 9 quarters. The position peaked at $11.5M in Q2 2024. 508 funds tracked by Wall St. Rank hold HALO as of Q4 2024.

  • Pier Capital reported no remaining Halozyme position as of Q4 2024 after selling out during the quarter.
  • Pier Capital sold 144,850 Halozyme shares in Q4 2024, an estimated $8.29M.
  • Pier Capital first reported a position in Halozyme in Q3 2022 and held it in 9 quarters.
  • Pier Capital's Halozyme position peaked at $11.5M in Q2 2024.
  • 508 funds tracked by Wall St. Rank held Halozyme as of Q4 2024.

Based on Pier Capital's 13F filing for Q4 2024, filed 11 Feb 2025.